European Journal of Immunology and Microbiology
ISSN: 2298-6555
Volume 01, Issue 01, August,2019

Developing A New Strategy for the Antitumor Immunotherapy: Pharmacological Modulation of the Ca2+/Camp Signaling Interaction

F. Bueno[1], L. Rodrigues[2]
Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), Brazil[1, 2.]

Abstract— Malignant growth is a noteworthy general medical issue and the subsequent driving reason for mortality around the globe. Antitumor immunotherapy utilizing monoclonal antibodies is viewed as particular and productive in the treatment of various sorts of tumors, yet its expense and poisonous impacts limit its application. Numerous tumor microenvironments, including lymphoma and carcinoma, are enhanced in insusceptible suppressive cells that add to safe fatigue by methods articulation of inhibitory ligands, suppressive cytokines, and tumor-advancing elements. Antitumor treatments focused to decrease the enlistment, enrollment, or suppressive exercises of the invulnerable cells have been explored. New antitumor techniques utilizing medications focused to intracellular flagging engaged with cell expansion and survival, angiogenesis, and metastasis have turned out to be promising as of late. In this way, our disclosure of the job of utilitarian association between intracellular flagging pathways intervened by calcium particles (Ca2+) and cyclic adenosine monophosphate (cAMP) (Ca2+/cAMP flagging connection) in these cell reactions, opened an extraordinary road for the advancement of new antitumor remedial methodologies. Here, we examine how the joined utilization of monoclonal antibodies with medications that balance the Ca2+/cAMP flagging communication to diminish tumor development could be a potential procedure in the antitumor immunotherapy because of the addition of antitumor viability and decrease of unfriendly impacts.

Keywords— Ca2+/cAMP Signaling Interaction; Antitumor Immunotherapy.

1. Introduction

As indicated by the World Health Organization (WHO) reports, malignant growth is the second driving worldwide reason for death. These reports demonstrated that the disease was in charge of 8.8 million passings in worldwide just in 2015. Be that as it may, the quantity of new malignancy cases can ascend by about 70% throughout the following 2 decades. Regular chemotherapy and radiotherapy have demonstrated significant confinements, predominantly because of its high level of unwanted symptoms, low selectivity, and for influencing both tumor and sound cells [1,2]. Hence, new antitumor systems, for example, directed treatments [3] and immunotherapy [4] have been proposed as monotherapy, or in blend with regular treatments [5].

Antitumor immunotherapy utilizing monoclonal antibodies, for example, antibodies against vascular endothelial development factor (VEGF), has been considered as palatable focused on and specific antitumor treatment [6]. In spite of the fact that this methodology has indicated huge antitumor viability in the distinctive tumor types, the lethal impacts and surprising expense confines its current clinical use [7]. In this manner, the viability, mediocrity and cost of the antitumor immunotherapy to control the tumor

development, angiogenesis and dispersal establish the significant boundaries for the advancement of successful antitumor treatment [8].

In the beginning periods, the mass tumor improvement is encouraged by dissemination of supplements through from neighboring tissues. Along these lines, tumor development relies upon the procedure of angiogenesis, and the new framed veins fill in as courses for scattering of the tumor cells to different spots [9]. For tumor-initiated angiogenesis happening, αvβ3 integrins assume a significant job in the physical cooperation with the extracellular grid important for cell bond, movement and situating, notwithstanding prompting signs for cell multiplication and survival [10]. The data transmitted by integrins from the extracellular medium to cytoskeleton proteins is intervened by a few intracellular flagging, including the expansion of GTPases movement, incitement of mitogen-initiated protein kinase (MAPK), modification of cytosolic Ca2+ fixation ([Ca2+]c), and increment of substrates enacted by phospholipase C (PLC) [11] [12].

Enactment of PLC animates the hydrolysis of film phospholipids, producing inositol-1-4-5-triphosphate (IP3), and diacylglycerol (DAG) [12]. DAG encourages the Ca2+ deluge through plasma layer voltage-initiated Ca2+ channels (Cav), expanding the [Ca2+]c [12,13]. The initiation of Ca2+ directs situated in endoplasmic reticulum (ER) layer by IP3 (by means of IP3 receptors) or Ca2+ (by means of ryanodine receptors) animate the Ca2+ discharge from ER to the cytosol, expanding the [Ca2+]c in explicit intracellular locales [12]. A few components engaged with intracellular Ca2+ homeostasis finely direct the [Ca2+]c [12]. The Ca2+ ATPases situated in ER film (SERCA) and plasma layer (PMCA) transport the Ca2+ from cytosol to ER and extracellular medium, individually, lessening the [Ca2+]c [12,13]. A few confirmations propose that the irregular quality articulation and movement of the various proteins engaged with the intracellular Ca2+ homeostasis, for example, Cav1.2, Cav3.2, SERCA2 and SERCA3, significantly add to tumor development and spread due to cytosolic Ca2+ over-burden in tumor cells [14-18]. Subsequently, these proteins establish potential sub-atomic focuses for antitumor treatment.

Notwithstanding intracellular Ca2+ flagging, other flagging and flag-bearers could add to tumor development and dispersal, for example, intracellular flagging intervened by cyclic adenosine monophosphate (cAMP). Created from the activity of adenylyl cyclases (AC) on the adenosine triphosphate (ATP), the cAMP is a significant intracellular flag-bearer associated with the guideline of a few cell reactions, including angiogenesis and tumor development [19-21]. The expansion of AC movement increases the cytoslic cAMP fixation ([cAMP]c) that dynamic protein kinases, for example, cAMP-subordinate protein kinase (PKA), coming about a few cell reactions [19-21]. The reduction of AC action diminishes the [cAMP]c and intracellular cAMP flagging that controls the transcriptional elements, and quality initiation, animating DNA union and cell cycle [19-21]. A few confirmations recommend that the expansion of [cAMP]c represses the angiogenesis and tumor development [21-24]. In this way, delivery person associated with the intracellular cAMP flagging likewise comprise potential atomic focuses for antitumor treatment.

It is settled that the Ca2+ finely manages the AC action, and thusly the [cAMP]c, essentially in every mammalian cell, describing the useful collaboration between the intracellular flagging intervened by Ca2+ and cAMP (Ca2+/cAMP flagging connection) [25,26]. By methods the pharmacological balance of the Ca2+/cAMP flagging association, we found that this connection runs a significant cooperation in the

European Journal of Immunology and Microbiology
ISSN: 2298-6555
Volume 01, Issue 01, August,2019

diverse cell reaction, incorporating into synapse/hormone exocytosis and cell survival [26-30]. The Ca2+/cAMP flagging connection finely controls the [Ca2+]c controlling the various strides of exocytosis, for example, traffic and docking of secretory vesicle containing synapse and hormone [26-30]. What's more, the Ca2+/cAMP flagging connection take an interest in the guideline of cell survival interceded by cAMP/PKA/CREB [26-30].



Figure 1: Pharmacolo Caricati-Neto and Bergantin [26-30]. Th d by consolidated utilization of the Ca2+ [cAMP]c (cAMP-enhancer mixes). In li Ca2+ channels (L) delivered by CCB, th ntiated by cAMP-enhancer mixes, for ex

A few confirmations and cAMP could be engaged with tur e strange quality articulation and mov sis add to tumor development [14-18 esis and tumor development [21-24 n of monoclonal antibodies with me diminish tumor development could b augmentation of antitumor adequacy and decrease of antagonistic impacts [31-37]. Figure 1 demonstrates how the Ca2+/cAMP flagging cooperation could be pharmacologically balanced by the joined utilization of the Ca2+ channel blockers (CCB) and medications that advance the expansion of [cAMP]c (cAMP-enhancer mixes).

2. Pharmacological balance of the Ca2+/cAMP flagging cooperation as another remedial technique in tumor immunotherapy

In tumor cells, the intracellular Ca2+ flagging pathways are renovated, or deregulated, changing their physiology, and recognize them from non-threatening cells [38,39]. This renovating, or deregulation, gives implies by which malignant growth cells can beat foundational anticancer guard instruments [38,39]. Likewise, this rebuilding or deregulation can prompt hereditary decent variety found in disease tissues subsequently giving viable cell techniques to the determination strain to gain explicit attributes [38,39].

A few confirmations recommend that the cytosolic Ca2+ over-burden because of strange quality articulation and action of the various sorts of Ca2+ channels critically add to tumor development and spread due to cytosolic Ca2+ over-burden in tumor cells [14-18]. Confirmations recommend that Ca2+ channels TRP and Orai take part in the intracellular Ca2+ flagging included the physiological angiogenesis forms [17]. Accordingly, the Ca2+ channels have turned out to be significant atomic focuses in tumor cells and the medications that meddle with the Ca2+ directs could be helpful in the treatment of various sorts of tumor [18,31-37,40,41].

L-type Ca2+ directs has been embroiled in the advancement and movement of a few tumors, and an ongoing meta-investigation of microarray datasets demonstrated that mRNA quality profile of the L-type Ca2+ diverts in various sorts of malignant growth [42-47]. For instance, it was demonstrated that the L-

type Ca2+ channels are altogether up-controlled in colon and esophageal malignancy [43-47]. In this manner, pharmacological bar of these channels could be utilized as a remedial methodology for antitumor treatment. Truth be told, a few examinations demonstrated that the L-type CCB, for example, amlodipine, mibefradil and NNC-55-0396, hinder the proliferative reaction in various tumor cells [18,40,41]. It was proposed that these L-type CCB can legitimately adjust the interpretation of qualities and their items, e.g., the proteolytically cut 75 kDa C-terminal section of Cav1.2, a Ca2+ channel related transcriptional controller (CCAT), which translocates to the core changing the translation of a few qualities, including Myc, Bcl-related demise advertiser (Bad) and artemin [42]. Atomic CCAT levels increment or abatement in light of low and high intracellular Ca2+, respectively [42].

It was recommended that L-type CCB NNC 55-0396 hinders tumor angiogenesis by concealment of hypoxia-inducible factor-1alpha sign transduction by means of both proteasome debasement, and protein amalgamation pathways [18]. The L-type CCB Amlodipine hindered both in vitro and in vivo the development of human epidermoid carcinoma A431 cells, by means of capturing cell cycle at G1 stage, and diminishing phosphorylation of retinoblastoma protein, articulation levels of cyclin D1 and cyclin subordinate kinase [40]. Novel graft variations of T-type Ca2+ directs are ordinarily recognized in human glioma, bosom, ovarian, prostate colon and esophageal malignancy cells [43-47]. Cav3.1 transcript prevail in the typical grown-up mind, however human glioma and glioma cell lines contain Cav3.1 as dominating graft and Cav3.1 as a novel join variation, which is missing in ordinary cerebrum Ca2+ channels [43-47]. Mibefradil, a T-and L-type CCB, decreased tumor size, to improve the survival rate in glioma creature model just as in a patient determined pancreas xenograft creature model [43,48]. An epic mibefradil-inferred compound NNC-55-0396 repressed angiogenesis in tumor cells, turning into a promising chemotherapy medicate [18,43]. Proangiogenic occasions intervened by Ca2+ have been explored in tumor-inferred endothelial cells [17]. Irregular articulation and capacity of Transient Receptor Potential (TRP) directs is engaged with the adjustments of intracellular Ca2+ motioning in endothelial cells from human bosom and kidney tumors and [17]. TRP channels subfamily incorporates various putative proangiogenic channels [17]. It was proposed that pharmacological barricade of these Ca2+ channels could altogether lessen the vascularization in these tumors [17]. In this way, antitumor immunotherapy utilizing monoclonal antibodies against VEGF, has been considered as agreeable focused on and specific antitumor treatment [6]. These discoveries bolster that the pharmacological tweak of the various sorts of Ca2+ diverts in the tumor cells joined with monoclonal antibodies against VEGF could be a novel option for antitumor immunotherapy.

A few confirmations propose that the medications that balance the intracellular cAMP flagging could be utilized to hinder the angiogenesis and tumor development. It likewise was demonstrated that the expansion of [cAMP]c delivered by phosphodiesterase (PDE) inhibitors stifle the endothelial extracellular grid rebuilding [22]. Likewise, it was demonstrated that PDE inhibitors lessen the intracellular flagging interceded by PI3K/AKT to down-tweak VEGF emission and vessel development in vitro, and stimuling the lower amalgamation of VEGF and decreasing the microvessel thickness in creature model of diffuse enormous B-cell lymphoma [23]. A few examinations demonstrated that the relationship of PDE2 and PDE4 inhibitors with curcumin fundamentally decreased the VEGF creation, angiogenesis and tumor development [24].

It was demonstrated that the expansion of [cAMP]c prompted by AC activator forskolin delivered noteworthy antitumor impacts [49]. The 8-Cl-cAMP, and the PKA I-particular cAMP analogs (8-piperidinoadenosine - 3',5'- cyclic monophosphate (8-PIP-cAMP) and 8-hexylaminoadenosine - 3',5'-cyclic monophosphate (8-HA-cAMP) created a critical antiproliferative impacts in human malignant growth cell lines [50]. The counter proliferative impact of the PKA I-particular cAMP analogs was ascribed to development capture, while the 8-Cl-cAMP shows up be because of star apoptotic impact [50]. It likewise seen that the PKA I-specific cAMP analogs, yet not 8-Cl-cAMP, restrained ERK phosphorylation, though 8-Cl-cAMP alone instigated a dynamic phosphorylation of the p38 MAPK through actuation of AMPK by its metabolite 8-Cl-adenosine [51]. Pharmacological hindrance of the p38 MAPK anticipated the master apoptotic impact of 8-Cl-cAMP [51]. These discoveries propose that 8-Cl-cAMP and the PKA I-specific cAMP analogs could be utilized in human tumor treatment.

Strikingly, the 8-Cl-cAMP and PKA type I-particular cAMP analogs (8-PIP-cAMP and 8-HA-cAMP) additionally demonstrated a powerful antiproliferative impact in medullary thyroid malignant growth cell lines [52]. It was demonstrated that the 8-Cl-cAMP fundamentally restrained the progress of cell populace from G2/M to G0/G1 stage and from G0/G1 to S stage [51]. What's more, the 8-Cl-cAMP initiated apoptosis in medullary thyroid malignant growth cell lines [52]. This finding showed that cAMP analogs, especially 8-Cl-cAMP, essentially smother cell expansion in medullary thyroid malignant growth cell lines and give basis to a potential clinical utilization of medications that meddle with intracellular flagging intervened by cAMP/PKA in the antitumor treatment. In spite of the fact that the job of intracellular cAMP motioning in tumor cells has been inadequately explored, the medications that meddle in the intracellular cAMP fixation have been proposed as potential adjuvant, chemotherapeutic or chemopreventive operators in various sorts of malignant growth, including hepatocellular carcinoma [53]. Because of contribution of Ca2+ and cAMP in the guideline of the few cell reactions, including angiogenesis and tumor development, the proteins engaged with the Ca2+/cAMP flagging association have been viewed as potential pharmacological focuses in the antitumor treatment, in blend with traditional chemotherapy, radiotherapy and immunotherapy. Mention that the disease treatment with medications that adjust the Ca2+/cAMP flagging association could be helpful to control development of malignancy with high rates of protection from traditional immunotherapy, to diminish portion of monoclonal antibodies intravenously injected, and their unfavorable impacts. Subsequently, the pharmacological regulation of the Ca2+/cAMP flagging association in tumor cells could open an incredible road for the improvement of new antitumor restorative techniques to lessen tumor development by joined utilization of the CCB, drugs that meddle with cAMP flagging and hostile to VEGF monoclonal antibodies. This new system could advance significant advances in the antitumor immunotherapy, expanding its adequacy and diminishing symptoms.

3. References

1. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, et al. Cancer incidence in five continents: Inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer 137 (2015): 2060-2071.
2. Azar FE, Azami-Aghdash S, Pournaghi-Azar F, Mazdaki A, Rezapour A, et al. Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews. BMC Healt Serv Res. 17 (2017): 413.

3. Larkin J, O´Reilly A. The safety of nivolumab for the treatment of metastatic melanoma. Expert Opin Drug Saf 16 (2017): 955-961.

4. Hahan AW, Gill DM, Pal SK, Agarwal N. The future of imune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy 9 (2017): 681-692.

5. Visconti R, Morra F, Guggino G, Celetti A. The between now and then of lung concer chemotherapy and immunotherapy. Int J Mol Sci 18 (2017): E1374.

6. Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: Regulators and clinical implications. Med Res Rev (2017).

7. Diaz RJ, Ali S, Qadir MG, De La Fuente MI, et al. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol (2017).

8. de Miguel-Luken MJ, Mansinho A, Boni V, Calvo E. Immunotherapy-based combinations: current status and perspectives. Curr Opin Oncol (2017).

9. De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumor angiogenesis. Nat Rev Cancer (2017).

10. Demircioglu F, Hodivala-Dilke K. αvβ3 integrin and tumor blood vessels-learning from the past to shape the future. Curr Opin Cell Biol 42 (2016): 121-127.

11. Atkinson SJ, Ellison TS, Steri V, Gould E, Robinsosn SD. Redefining the role(s) of endotheial αvβ3-integrin in angiogenesis. Biochem Soc Trans 42 (2014): 1590-1595.

12. Pechkovsky DV, Scaffidi AK, Hackett TL, Ballard J, Shaheen F, et al. Transforming growth factor beta 1 induces alphavbeta3 integrin expression. In human lung fibroblast via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem 283 (2008): 12898-12908.

13. Nakamura Y, Fukami K. Regulation and physiological functions of mammalian phospholipase C. J Biochem 161 (2017): 315-321.

14. Busselberg D, Florea AM. Targeting intracellular calcium signaling ([Ca2+] i) to overcome acquired multidrug resistance of cancer cells: A mini-review. Cancer (2017): E48.

15. Parkash J, Asotra K. Calcium wave signaling in cancer cells. Life Sci 87 (2010): 587-595.

16. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 287 (2012): 31666-31673.

17. Munaron L, Genova T, Avanzato D, Antoniotti S, Fiorio Pla A. Targeting calcium channels to block tumor vascularization. Recent Pat Anticancer Drug Discov 8 (2013): 27-37.

18. Kim KH, Kim D, Park JY, Jung HJ, Cho YH, et al. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via supression of hypoxia-inducible factor-1alpha signal transduction. J Mol Med 93 (2015): 499- 509.

19. Krasteva PV, Sondermann H. Versatile modes of cellular regulation via cyclic dinucleotides. Nat Chem Biol 13 (2017): 350-359.

20. Xiao LY, Kan WM. Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells. Eur J Pharmacol 794 (2017): 201-208.

21. Neto A, Ceol CJ. Melanoma-associated GRM3 variantes dysregulate melanosome trafficking and cAMP Signaling. Pigment Cell Melanoma Res (2017): 24.

22. Yun S, Budatha M, Dahlman JE, Coon BG, Cameron RT, et al. Interaction between integrin α5 and PDE4D regulates endotelial inflammatory signalling. Nat Cell Biol 18 (2016):1043-1053.

23. Suhasini NA, Wang L, Holder KN, Lin AP, Bhatnagar H, et al. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma. Leukemia 30 (2016): 617-626.

24. Abusnina A, Keravis T, Zhou Q, Justiniano H, Lobstein A, et al. Tumor groth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Thromb Haemost 113 (2015): 319-328.

25. Bergantin LB, Souza CF, Ferreira RM, Smaili SS, Jurkiewicz NH, Caricati-Neto A, Jurkiewicz A. Novel model for "calcium paradox" in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium 54(2013): 202-212.

26. Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca2+/cAMP signalling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect 3 (2015): 1-10.

27. Caricati-Neto A, Bergantin LB. New therapeutic strategy of Alzheimer´s and Parkinson´s diseases: Pharmacological modulation of neural Ca2+/cAMP intracellular signaling interaction. Asian J Pharm Pharmacol 2 (2016)): 136-143.

28. Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca2+/cAMP intracellular signalling interaction. Eur J Pharmacol 788 (2016): 255-260.

29. Bergantin LB, Caricati-Neto A. Recent advances in pharmacotherapy of neurological and psychiatric disorders promoted by discovery of the role of Ca2+/cAMP signaling interaction in the neurotransmission and neuroprotection. Adv Pharmac J 1 (2016): 66-69.

30. Bergantin LB, Caricati-Neto A. From discovering “calcium paradox” to Ca2+/cAMP interaction: Impact in human health and disease. Scholars Press (2016).

31. Caricati-Neto A, Errante PR, Bergantin LB. A novel alternative for cancer therapy: Pharmacological modulation of Ca2+/cAMP intracellular signaling interaction. Am J Pharmacol Pharmacother 4 (2017): 20-34.

32. Errante PR, Menezes-Rodrigues FS, Leite AA, Caricati-Neto A, Bergantin LB. New antitumoral pharmacological strategies involving Ca2+/cAMP signaling pathways. J Cancer Epidem Prev 2 (2017): 1-6.

33. Errante PR, Caricati-Neto A, Bergantin LB. Insights for the inhibition of cancer progression: Revisiting Ca2+ and cAMP signalling pathways. Adv Cancer Prev 2 (2017): 1-2.

34. Errante PR, Menezes-Rodrigues FS, Caricati-Neto A, Bergantin LB. The pharmacological modulation of Ca2+/cAMP intracellular signaling pathways and traditional antitumoral pharmaceuticals: a plausible multitarget combined therapy? J Clin Exper Oncol 6 (2017): 1-3.

35. Errante PR, Menezes-Rodrigues FS, Leite AA, Caricati-Neto A, Bergantin LB. The second messengers Ca2+ and cAMP as potential therapeutic targets for the control of cancer progression. Adv Cancer Prev 2 (2017): 1- 2.

36. Errante PR, Leite AA, Menezes-Rodrigues FS, Caricati-Neto A, Bergantin LB. A novel potential therapeutic target as adjuvant treatment for cancer: the pharmacological interference on the Ca2+/cAMP cellular signaling pathways. Enliven: Chall Cancer Detec Ther 1 (2017): 1-2.

37. Menezes-Rodrigues FS, Errante PR, Caricati-Neto A, Bergantin LB. Extracellular cyclicAMP/Adenosine signaling pathway: a potential pharmacological target for therapeutic intervention in chronic lymphocytic leukemia. Adv Cancer Prev 2 (2017): 1-2.

38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100 (2007): 57-70.

39. Wang XT, Nagaba Y, Cross HS. The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 57 (2007): 1549-62.

40. Yoshida J, Ishibashi T, Nishio M. G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem Pharmacol 73 (2007): 943-53.

41. Krouse AJ, Gray L, Macdonald T, et al. Repurposing and rescuing of mibefradil, an antihypertensive, for cancer: a case study. Assay Drug Dev Technol 13 (2015): 650-653.

42. Gomez-Ospina N, Tsuruta F, Barreto-Chang O, et al. The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor. Cell 127 (2006): 591-606.

43. Kale VP, Amin SG, Pandey MK. Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Biophys Acta (BBA) –Biomembr 1848 (2015): 2747-2755.

44. Dziegielewska B, Gray LS, Dziegielewski J. T-type calcium channels blockers as new tools in cancer therapies. Pflugers Arch 466 (2014): 801-810.

45. Ohkubo T, Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol 41 (2012): 267-275.

46. Gackière F, Bidaux G, Delcourt P, et al. CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells. J Biol Chem 283 (2008): 10162-10173.

47. Latour I, Louw DF, Beedle AM, et al. Expression of T-type calcium channel splice variants in human glioma. Glia 48 (2004): 112–119.

48. Garrido-Laguna I, Tan AC, Villarroel MC, et al. Activity of the T-type calcium channel antagonist Mibefradil in pancreatic cancer xenografts. Clin Cancer Res 14 (2008): 49-49.

49. Murray F, Insel PA. Targeting cAMP in chronic lymphocytic leukemia: A pathway-dependent approach for the treatment of leukemia and lymphoma. Expert Opin Ther Targets 17 (2013): 937-949.

50. Sapio L, Gallo M, Illiano M. The natural cAMP elevating compound forskolin in cancer therapy: is it time? J Cell Physiol 232 (2017): 922-927.

51. Lucchi S, Calebiro D,Filippis T, et al. 8-chloro-cyclic AMP and protein kinase A I-selective cyclic AMP analogs inhibit cancer cell growth through different mechanisms. PLoS One 6 (2017): e20785.

52. Dicitore A, Grassi ES, Caraglia M, et al. The cAMPanalogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. Endocrine. 51 (2016): 101-112.

53. Massimi M, Cardarelli S, Galli F, et al. Increase of intracellular cyclic AMP by PDE4 inhibitors affects HepG2 cell cycle progression and survival. J Cell Biochem 118 (2017): 401-411.

This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License.